Use of Antisense Vectors and Oligodeoxynucleotides in Neuro-Oncology

This publication has 16 references indexed in Scilit:

• Consequences of Replacing the DNA 3‘-Oxygen by an Amino Group: High-Resolution Crystal Structure of a Fully Modified N3‘ → P5‘ Phosphoramidate DNA Dodecamer Duplex
  Journal of the American Chemical Society, 1998
• Suppression of insulin-like growth factor type I receptor by a triple-helix strategy inhibits IGF-I transcription and tumorigenic potential of rat C6 glioblastoma cells
  Proceedings of the National Academy of Sciences, 1997
• Mixed-backbone oligonucleotides as second generation antisense oligonucleotides: In vitro and in vivo studies
  Proceedings of the National Academy of Sciences, 1997
• Developing antisense oligonucleotides from the laboratory to clinical trials
  Drug Discovery Today, 1996
• Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor.
  Proceedings of the National Academy of Sciences, 1996
• Facilitating oligonucleotide delivery: helping antisense deliver on its promise.
  Proceedings of the National Academy of Sciences, 1996
• Antisense-Oligonucleotide Therapy
  New England Journal of Medicine, 1996
• Progress in Antisense Oligonucleotide Therapeutics
  Annual Review of Pharmacology and Toxicology, 1996
• Antisense oligonucleotide strategies in neuropharmacology
  Trends in Pharmacological Sciences, 1994
• Antisense RNA Control in Bacteria, Phages, and Plasmids
  Annual Review of Microbiology, 1994